These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9118471)

  • 1. Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide.
    Webster LK; Linsenmeyer ME; Rischin D; Urch ME; Woodcock DM; Millward MJ
    Cancer Chemother Pharmacol; 1997; 39(6):557-60. PubMed ID: 9118471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.
    Loos WJ; Baker SD; Verweij J; Boonstra JG; Sparreboom A
    Clin Pharmacol Ther; 2003 Oct; 74(4):364-71. PubMed ID: 14534523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly schedules of docetaxel.
    Burris H
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):21-3. PubMed ID: 9865688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
    D'Incalci M; Schüller J; Colombo T; Zucchetti M; Riva A
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):16-20. PubMed ID: 9865687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel.
    Rischin D; Webster LK; Millward MJ; Linahan BM; Toner GC; Woollett AM; Morton CG; Bishop JF
    J Natl Cancer Inst; 1996 Sep; 88(18):1297-301. PubMed ID: 8797769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel (Taxotere) administered in weekly schedules.
    Greco FA
    Semin Oncol; 1999 Jun; 26(3 Suppl 11):28-31. PubMed ID: 10458208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
    Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80.
    Ellis AG; Crinis NA; Webster LK
    Cancer Chemother Pharmacol; 1996; 38(1):81-7. PubMed ID: 8603456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
    Petrylak DP
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.
    Webster L; Linsenmeyer M; Millward M; Morton C; Bishop J; Woodcock D
    J Natl Cancer Inst; 1993 Oct; 85(20):1685-90. PubMed ID: 8105099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.
    van Tellingen O; Beijnen JH; Verweij J; Scherrenburg EJ; Nooijen WJ; Sparreboom A
    Clin Cancer Res; 1999 Oct; 5(10):2918-24. PubMed ID: 10537361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel (Taxotere) in combination: a step forward.
    Burris HA; Fields S; Peacock N
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly administration of docetaxel (Taxotere): summary of clinical data.
    Hainsworth JD; Burris HA; Greco FA
    Semin Oncol; 1999 Jun; 26(3 Suppl 10):19-24. PubMed ID: 10437747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
    Sparreboom A; Verweij J; van der Burg ME; Loos WJ; Brouwer E; Viganò L; Locatelli A; de Vos AI; Nooter K; Stoter G; Gianni L
    Clin Cancer Res; 1998 Aug; 4(8):1937-42. PubMed ID: 9717822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
    Burris HA
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):19-23. PubMed ID: 10810934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats.
    Kamijo Y; Ito C; Nomura M; Sai Y; Miyamoto K
    Cancer Lett; 2010 Jan; 287(2):182-6. PubMed ID: 19608331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer.
    Fossella FV; Lee JS; Berille J; Hong WK
    Semin Oncol; 1995 Apr; 22(2 Suppl 4):22-9. PubMed ID: 7740327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a place for "dose-dense" weekly schedules of the taxoids?
    Löffler TM
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):32-4. PubMed ID: 9865710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress in the clinical development of docetaxel (Taxotere).
    Hortobagyi GN
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
    Van Den Neste E; de Valeriola D; Kerger J; Bleiberg H; Kusenda Z; Brassinne C; Bartholomeus S; Selleslags J; Hennebert P; Wythouck H; Cazenave I; Lefresne-Soulas F; Piccart M
    Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.